Kineta (KA) News Today $0.64 -0.04 (-5.86%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 8, 2024 | globenewswire.comKineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA BiosciencesJuly 8, 2024 | prnewswire.comTuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint InhibitorMay 16, 2024 | morningstar.comKineta Inc KAMay 15, 2024 | msn.comKA Stock Earnings: Kineta Misses EPS for Q1 2024May 15, 2024 | globenewswire.comKineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate ActivitiesApril 18, 2024 | msn.comKineta (KA) Price Target Increased by 25.58% to 13.77April 9, 2024 | finanznachrichten.deKineta, Inc.: Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialApril 8, 2024 | globenewswire.comKineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialMarch 22, 2024 | finanznachrichten.deKineta, Inc.: Kineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 21, 2024 | globenewswire.comKineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | globenewswire.comKVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data ReportedMarch 1, 2024 | bizjournals.comKineta CEO laid off as cutbacks leave biotech with 4 employeesFebruary 29, 2024 | msn.comKineta stock falls ~25.7% after co cuts workforce by 64%, including CEOFebruary 29, 2024 | globenewswire.comKineta Announces Restructuring and Exploration of Strategic AlternativesFebruary 22, 2024 | finance.yahoo.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumFebruary 22, 2024 | globenewswire.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumFebruary 14, 2024 | finance.yahoo.comKineta to Present at Upcoming Investor ConferencesFebruary 14, 2024 | globenewswire.comKineta to Present at Upcoming Investor ConferencesFebruary 7, 2024 | stockhouse.comKineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat SeriesJanuary 29, 2024 | finance.yahoo.comKA: Phase I/II UpdateJanuary 17, 2024 | finanznachrichten.deKineta, Inc.: Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid TumorsDecember 13, 2023 | finance.yahoo.comKineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for CancerDecember 12, 2023 | finance.yahoo.comKineta to Present at the Life Sciences Investor Forum December 14thNovember 28, 2023 | finance.yahoo.comKineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023November 9, 2023 | finance.yahoo.comKineta to Present at the 5th Annual Macrophage-Directed Therapies SummitNovember 8, 2023 | markets.businessinsider.comBuy Rating for Kineta Backed by Promising Drug Trials and Solid Financial PerformanceNovember 7, 2023 | msn.comKA: Third Quarter Results - MSNNovember 7, 2023 | finance.yahoo.comKA: Third Quarter ResultsNovember 6, 2023 | benzinga.comKineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingNovember 6, 2023 | finance.yahoo.comKineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNovember 4, 2023 | finance.yahoo.comKineta Insider Purchases Yet To Pay Off Regardless Of Recent StrengthNovember 4, 2023 | finanznachrichten.deKineta, Inc.: Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 3, 2023 | benzinga.comKineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingNovember 3, 2023 | chron.comKineta: Q3 Earnings SnapshotNovember 3, 2023 | finance.yahoo.comKineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNovember 3, 2023 | finance.yahoo.comKineta Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 18, 2023 | markets.businessinsider.comPromising Prospects for Kineta’s VISTA-101 Trial and KVA12123 Monotherapy Drive Buy RatingOctober 17, 2023 | finance.yahoo.comKineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsOctober 12, 2023 | finance.yahoo.comKA: Autumn ActivityOctober 12, 2023 | finance.yahoo.comKineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023October 12, 2023 | marketbeat.comTrading was temporarily halted for "KA" at 10:10 AM with a stated reason of "LULD pause."October 9, 2023 | finance.yahoo.comKineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023October 5, 2023 | finance.yahoo.comKineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesOctober 4, 2023 | finance.yahoo.comKineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesOctober 4, 2023 | finance.yahoo.comKineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and ImmunotherapySeptember 28, 2023 | finance.yahoo.comKineta Announces Participation at October Investor ConferencesSeptember 25, 2023 | finance.yahoo.comKineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and ImmunotherapySeptember 18, 2023 | finance.yahoo.comKineta Announces New Research Agreement to Evaluate VISTA Biomarker ExpressionSeptember 16, 2023 | finance.yahoo.comInsider Buying: Thierry Guillaudeux Acquires 10,000 Shares of Kineta IncAugust 31, 2023 | finance.yahoo.comKineta to Participate in Upcoming Investor Conferences Get Kineta News Delivered to You Automatically Sign up to receive the latest news and ratings for KA and its competitors with MarketBeat's FREE daily newsletter. Email Address Collapse of the Petrodollar (Ad)The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. In answer to this issue, we have released a Special Report to the public. KA Media Mentions By Week KA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KA News Sentiment▼0.440.62▲Average Medical News Sentiment KA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KA Articles This Week▼21▲KA Articles Average Week Get Kineta News Delivered to You Automatically Sign up to receive the latest news and ratings for KA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lipocine News Today LianBio News Today ImmuCell News Today Pluri News Today VYNE Therapeutics News Today NKGen Biotech News Today Reviva Pharmaceuticals News Today ZIVO Bioscience News Today Acasti Pharma News Today Surrozen News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kineta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kineta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.